Groups hails potential of organ on a chip tech for UK
The Medicines Discovery Catapult, the Centre for Drug Safety Sciences at the University of Liverpool and the National Centre for the Replacement Refinement & Reduction of Animals in Research are working together to “propel” the UK into the race to advance organ on a chip technology.
An organ on a chip (OOAC) is essentially a multi-channel 3D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems.
Although still in early stages, the technology is widely used and researched in the US and across Europe, and many believe it could revolutionise drug discovery and development.
According to the partners, the field represents a significant opportunity for UK researchers, as it has the potential to provide “sophisticated models of human organ systems which better mimic what happens when patients receive drug molecules; providing patient relevant data, enabling risk-free biomedical testing and reducing the need for animal disease models”.
Ultimately, this will save the UK drug discovery community vital time, resource and money, as well as significantly cut the number of failed trials and disappointments further down the line, the groups note.
Read more: http://www.pharmatimes.com/news/groups_hails_potential_of_organ_on_a_chip_tech_for_uk_1235484
An organ on a chip (OOAC) is essentially a multi-channel 3D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems.
Although still in early stages, the technology is widely used and researched in the US and across Europe, and many believe it could revolutionise drug discovery and development.
According to the partners, the field represents a significant opportunity for UK researchers, as it has the potential to provide “sophisticated models of human organ systems which better mimic what happens when patients receive drug molecules; providing patient relevant data, enabling risk-free biomedical testing and reducing the need for animal disease models”.
Ultimately, this will save the UK drug discovery community vital time, resource and money, as well as significantly cut the number of failed trials and disappointments further down the line, the groups note.
Read more: http://www.pharmatimes.com/news/groups_hails_potential_of_organ_on_a_chip_tech_for_uk_1235484